Serum YKL-40, but Not Relaxin-2, Shows Diagnostic Utility as an Adjunct Biomarker in Colorectal Cancer
Open Access
- 29 November 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (23) , 11601
Abstract
Despite the availability of conventional serum markers for colorectal cancer (CEA, CA 19-9), there remains a need for more sensitive and specific biomarkers, particularly for early-stage detection. This study evaluated the diagnostic usefulness of serum Relaxin-2 (RLN2) and Chitinase-3-like protein 1 (YKL-40) as potential adjunct markers in patients with CRC. Serum concentrations of all the proteins were measured using a multiplexing assay and CMIA and were subsequently compared using non-parametric statistical tests. The concentrations of YKL-40, CEA, and CA 19-9 were elevated in CRC patients relative to controls (p < 0.05), but not so for RLN2. The concentrations of YKL-40 were also significantly elevated in patients undergoing chemotherapy or preoperative radiotherapy referral. Kruskal–Wallis and post-hoc testing found that YKL-40 and CEA were associated with tumor progression, but RLN2 and CA 19-9 were increased primarily in advanced, metastatic disease. No statistically significant differences in marker levels were observed between cancer subtypes or between histologic grades. Performance analysis for diagnostic purposes showed YKL-40 was moderately sensitive (65%) but very specific (77.5%), and its AUC was 0.702, higher than CA 19-9 (AUC = 0.632) but lower than CEA (AUC = 0.869) (all p < 0.05). RLN2 did not reach statistical significance (AUC = 0.593, p = 0.09). Correlation analysis demonstrated the best correlation with disease stage for CEA and weaker positive correlations for YKL-40, CA 19-9, and RLN2. These findings suggest that YKL-40 may serve as a useful adjunct serum biomarker for CRC diagnosis, especially when combined with conventional markers such as CEA.Keywords
Funding Information
- Uniwersytet Medyczny w Bialymstoku (B.SUB.25.517)
This publication has 51 references indexed in Scilit:
- Global trends and epidemiological shifts in gastrointestinal cancers: insights from the past four decadesCancer Communications, 2025
- The dual and multifaceted role of relaxin-2 in cancerClinical and Translational Oncology, 2023
- Knockdown of YKL‐40 inhibits angiogenesis through regulation of VEGF/VEGFR2 and ERK1/2 signaling in endometrial cancerCell Biology International, 2021
- YKL-40 Promotes Proliferation of Cutaneous T-Cell Lymphoma Tumor Cells through Extracellular Signal–Regulated Kinase PathwaysJournal of Investigative Dermatology, 2020
- Relaxin-FOLFOX-IL-12 triple combination therapy engages memory response and achieves long-term survival in colorectal cancer liver metastasisJournal of Controlled Release, 2020
- Early diagnosis of acute kidney injury by urinary YKL-40 in critically ill patients in ICU: a pilot studyInternational Urology and Nephrology, 2020
- Identification of a novel fusion transcript between human relaxin-1 (RLN1) and human relaxin-2 (RLN2) in prostate cancerMolecular and Cellular Endocrinology, 2016
- Elevated pretreatment serum concentration of YKL-40: An independent prognostic biomarker for poor survival in patients with colorectal cancerMedical Oncology, 2014
- Human relaxin-2: historical perspectives and role in cancer biologyAmino Acids, 2012
- Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesisInternational Journal of Cancer, 2000